Palantir spent the week widening what customers can do with its platform and deepening a hospital partnership, but the market’s attention keeps snapping back to a single uncomfortable number: 6%. That is the pace at which the company’s total contract value grew, and it sits awkwardly beside a revenue line that nearly doubled.
The contracts figure, reported at $2.918 billion, was enough to sour the mood on Wednesday even though headline results had cleared both sales and earnings expectations. Slower deal momentum and valuation worries were cited as the reasons for the subsequent share-price retreat. The stock reaction tells you where investors have decided the argument now lies.
Revenue races ahead of the order book
On November 2, Palantir posted third-quarter 2026 revenue of $2.313 billion, up 96% year on year. Commercial US customers did much of the heavy lifting: their revenue climbed 148% to $984 million, a first in which that segment out-earned the company’s US government business.
Yet the contract-value growth of 6% stands in sharp contrast to that top-line surge. Within the US commercial book the deceleration was even starker — contract value growth slowed to 11%, down from 153% previously. For anyone judging whether the growth story holds, those figures carry more weight than the revenue beat.
Freeing up the toolkit
Against that backdrop, the product announcements read as an attempt to convert technical capability into usage. On Thursday, Palantir made Ontology SQL and SQL functions generally available across all customer environments. The pitch is straightforward: the economic value of AI depends on how easily its tools slot into everyday work, and broader access only matters if it turns into heavier use and firmer contracts.
Two days earlier, the company unveiled a remote preview for SuperRepo applications drawing live data from the Ontology, with access limited to read-only and governed by users’ existing permissions. That combination — live data plus pre-existing entitlements — targets a practical question many enterprises face: how to trial new applications without rebuilding their access controls from scratch.
Cost is the other lever. On November 5, Palantir said it would cut compute costs for ongoing data ingestion through Foundry Worker by roughly 97.5%, effective November 1. Cheaper processing helps customers justify running more applications or running existing ones harder. Whether that translates into revenue for Palantir itself depends on usage and contract volume moving in step.
Should investors sell immediately? Or is it worth buying Palantir?
A hospital ward as proving ground
The clearest test case arrived the same day, when Tampa General Hospital said it would work with Palantir to develop analytics for its Reliability Management System, aimed at helping teams spot and address patient-safety risks. The stated purpose is narrow and checkable, which is precisely what makes it useful as a yardstick: the partnership can be measured against whether the tools actually assist staff in that task.
It also fits a broader shift in which data analytics moves closer to operational decisions. The value of that shift gets settled where an analytical insight has to become an action. A defined use case makes the claim more verifiable than another round of ever-larger growth numbers.
Palantir’s November 5 partnership with AmeriLife points the same way, targeting AI-driven transformation in the sale of insurance and retirement products. Deals like these tie product development to concrete business processes — and give the recent technical releases something to prove themselves against.
What would settle the debate
The bar is already high. Sustaining 96% growth requires new business to keep flowing in, which is why the contract metrics deserve close scrutiny. Lower costs on the customer side and greater economic value for the vendor only converge when usage and deal size follow.
My reading: Palantir’s work on usability and cost speaks in its favour, while the softer contract growth supplies a demanding cross-check. The two halves of the story need to meet. If customers convert the expanded toolkit into additional orders, the product progress acquires real financial weight for shareholders — and the 6% figure starts to look like a pause rather than a warning.
Ad
Palantir Stock: Buy or Sell?! New Palantir Analysis from November 14 delivers the answer:
The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 14.
Palantir: Buy or sell? Read more here...
